A Study of AK104 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer
- Conditions
- Lung Cancer Non-Small Cell Stage IIIB/IIIC/IV
- Interventions
- First Posted Date
- 2020-11-30
- Last Posted Date
- 2024-04-25
- Lead Sponsor
- Akeso
- Target Recruit Count
- 46
- Registration Number
- NCT04647344
- Locations
- 🇨🇳
Sun Yat-Sen University Cancer Center, Guanzhou, Guangdong, China
A Trial of AK104 Plus Anlotinib in NSCLC
- Conditions
- NSCLC
- Interventions
- Drug: AK104+anlotinib
- First Posted Date
- 2020-11-27
- Last Posted Date
- 2025-03-03
- Lead Sponsor
- Akeso
- Target Recruit Count
- 114
- Registration Number
- NCT04646330
- Locations
- 🇨🇳
Hunan cancer hospital, Changsha, Hunan, China
A Study of AK112 for Advanced Solid Tumors
- First Posted Date
- 2020-10-22
- Last Posted Date
- 2025-03-10
- Lead Sponsor
- Akeso
- Target Recruit Count
- 59
- Registration Number
- NCT04597541
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
A Study of AK119 (Anti-CD73) in Combination With AK104 in Subjects With Advanced Solid Tumors
- Conditions
- Advanced or Metastatic Solid Tumors
- Interventions
- First Posted Date
- 2020-10-01
- Last Posted Date
- 2025-02-28
- Lead Sponsor
- Akeso
- Target Recruit Count
- 23
- Registration Number
- NCT04572152
- Locations
- 🇦🇺
Monash Health, Clayton, Victoria, Australia
🇦🇺Alfred Health (The Alfred Hospital), Melbourne, Victoria, Australia
🇦🇺Ashford Cancer Centre, Adelaide, South Australia, Australia
A Study of Anti-VEGFR2 AK109 in Subjects With Advanced Solid Tumors
- First Posted Date
- 2020-09-14
- Last Posted Date
- 2023-02-23
- Lead Sponsor
- Akeso
- Target Recruit Count
- 40
- Registration Number
- NCT04547205
- Locations
- 🇨🇳
The First Affiliated Hospital of Medicine College, Zhejiang University, Hangzhou, Zhejiang, China
A Study of AK104 in Subjects With Locally Advanced Unresectable or Metastatic MSI-H/dMMR Solid Tumors
- First Posted Date
- 2020-09-14
- Last Posted Date
- 2022-10-19
- Lead Sponsor
- Akeso
- Target Recruit Count
- 6
- Registration Number
- NCT04547101
- Locations
- 🇨🇳
Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, China
A Study of PD-1/CTLA-4 Bispecific AK104 in Relapsed or Refractory Peripheral T-cell Lymphoma
- Conditions
- Peripheral T-cell Lymphoma
- Interventions
- Biological: AK104
- First Posted Date
- 2020-06-23
- Last Posted Date
- 2022-10-19
- Lead Sponsor
- Akeso
- Target Recruit Count
- 6
- Registration Number
- NCT04444141
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beiing, China
A Study of Anti-PD-1/CTLA-4 Bispecific AK104 Plus Lenvatinib in First-line Advanced Hepatocellular Carcinoma
- First Posted Date
- 2020-06-23
- Last Posted Date
- 2024-04-25
- Lead Sponsor
- Akeso
- Target Recruit Count
- 59
- Registration Number
- NCT04444167
- Locations
- 🇨🇳
Chinese PLA General Hospital, Beijing, Beijing, China
A Study of AK104, a PD-1/CTLA-4 Bispecific Antibody in Subjects With Recurrent/Metastatic Cervical Cancer
- Conditions
- Metastatic Cervical CancerRecurrent Cervical Cancer
- Interventions
- First Posted Date
- 2020-05-08
- Last Posted Date
- 2025-02-28
- Lead Sponsor
- Akeso
- Target Recruit Count
- 30
- Registration Number
- NCT04380805
- Locations
- 🇺🇸
Womens Cancer Research Foundation, Newport Beach, California, United States
🇺🇸BRCR Medical Center, Plantation, Florida, United States
🇺🇸Maryland Oncology Hematology (Plum Orchard), Silver Spring, Maryland, United States
A Study of PCSK9 Inhibitor AK102 in Patients With Hypercholesterolemia
- Conditions
- Hypercholesterolemia
- Interventions
- First Posted Date
- 2020-04-24
- Last Posted Date
- 2023-03-02
- Lead Sponsor
- Akeso
- Target Recruit Count
- 262
- Registration Number
- NCT04358432
- Locations
- 🇨🇳
Zhong Shan Hosipital Fu Dan University, Shanghai, China
🇨🇳Affiliated hospital of Guangdong medical university, Zhanjiang, China